| 559 | 1 | 33 |
| 下载次数 | 被引频次 | 阅读次数 |
mRNA疗法在当代医学领域展现出巨大的应用潜力。然而，由于mRNA分子的不稳定性和递送效率低下，该疗法依然面临诸多挑战。自新型冠状病毒mRNA疫苗成功研发并大规模应用于全球抗疫以来，mRNA疗法凭借其独特的技术优势和应用灵活性，已经成为应对多种疾病的一项开创性治疗手段。为了全面了解mRNA疗法的研究进展，本文首先介绍mRNA疗法的基本概念和关键技术；其次，总结mRNA疗法在传染病预防、癌症治疗、蛋白质替代治疗和基因编辑等方面的研究成果；最后，分析mRNA疗法面临的挑战，旨在为后续相关研究与临床应用提供全面而深入的理论参考与实践指导。
Abstract：mRNA therapy has demonstrated significant potential in the contemporary medical field. However, it is still meeting many challenges due to the instability of mRNA molecules and low delivery efficiency. Since the successful development and widespread application of the novel coronavirus mRNA vaccine, mRNA therapy has emerged as one of the most groundbreaking treatments for various diseases, leveraging its unique technical advantages and application flexibility. To comprehensively understand the progress in mRNA therapy, this paper first introduces the fundamental concepts and key technologies. It then summarizes the research achievements of mRNA therapy in infectious disease prevention, cancer treatment, protein replacement therapy, and gene editing. Finally, it analyzes the obstacles encountered by mRNA therapy, aiming to provide comprehensive theoretical references and practical guidelines for future research and clinical applications.
[1]BRENNER S,JACOB F,MESELSON M.An unstable intermediate carrying information from genes to ribosomes for protein synthesis[J].Nature,1961,13(190):576-581.DOI:10.1038/190576a0.
[2]HOU X,ZAKS T,LANGER R,et al.Lipid nanoparticles for m RNA delivery[J].Nat Rev Mater,2021,6(12):1078-1094.DOI:10.1038/s41578-021-00358-0.
[3]HUANG X,KONG N,ZHANG X,et al.The landscape of m RNA nanomedicine[J].Nat Med,2022,28(11):2273-2287.DOI:10.1038/s41591-022-02061-1.
[4]ZONG Y,LIN Y,WEI T,et al.Lipid nanoparticle(LNP) enables m RNA delivery for cancer therapy[J].Adv Mater,2023,35(51):e2303261.DOI:10.1002/adma.202303261.
[5]DIMITRIADIS G J.Translation of rabbit globin m RNAintroduced by liposomes into mouse lymphocytes[J].Nature,1978,274(5674):923-924.DOI:10.1038/274923a0.
[6]WOLFF J A,MALONE R W,WILLIAMS P,et al.Direct gene transfer into mouse muscle in vivo[J].Science,1990,247(4949 Pt 1):1465-1468.DOI:10.1126/science.1690918.
[7]MARTINON F,KRISHNAN S,LENZEN G,et al.Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped m RNA[J].Eur J Immunol,1993,23(7):1719-1722.DOI:10.1002/eji.1830230749.
[8]CONRY R M,LOBUGLIO A F,WRIGHT M,et al.Characterization of a messenger RNA polynucleotide vaccine vector[J].Cancer Res,1995,55(7):1397-1400.
[9]WEIDE B,PASCOLO S,SCHEEL B,et al.Direct injection of protamine-protected m RNA:results of a phase 1/2 vaccination trial in metastatic melanoma patients[J].J Immunother,2009,32(5):498-507.DOI:10.1097/CJI.0b013e3181a00068.
[10]BADEN L R,E L SAHLY H M,ESSINK B,et al.Efficacy and Safety of the m RNA-1273 SARS-Co V-2Vaccine[J].N Engl J Med,2021,384(5):403-416.DOI:10.1056/NEJMoa2035389.
[11]GU J,XU Z,LIU Q,et al.Building a better silver bullet:current status and perspectives of non-viral vectors for m RNA vaccines[J].Cancer Res Treat,2024,56(3):774-784.DOI:10.4143/crt.2023.1177.
[12]HUANG X,KONG N,ZHANG X,et al.The landscape of m RNA nanomedicine[J].Nat Med,2022,28(11):2273-2287.DOI:10.1038/s41591-022-02061-1.
[13]CHAUDHARY N,WEISSMAN D,WHITEHEADK A.m RNA vaccines for infectious diseases:principles,delivery and clinical translation[J].Nat Rev Drug Discov,2021,20(11):817-838.DOI:10.1038/s41573-021-00321-2.
[14]ALEXOPOULOU L,HOLT A C,MEDZHITOV R,et al.Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3[J].Nature,2001,413(6857):732-738.DOI:10.1038/35099560.
[15]KARIKóK,NI H,CAPODICI J,et al.m RNA is an endogenous ligand for Toll-like receptor 3[J].J Biol Chem,2004,279(13):12542-12550.DOI:10.1074/jbc.M310175200.
[16]MU X,HUR S.Immunogenicity of In Vitro-Transcribed RNA[J].Acc Chem Res,2021,54(21):4012-4023.DOI:10.1021/acs.accounts.1c00521.
[17]SCHLAKE T,THESS A,FOTIN-MLECZEK M,et al.Developing m RNA-vaccine technologies[J].RNA Biol,2012,9(11):1319-1330.DOI:10.4161/rna.22269.
[18]VERBEKE R,LENTACKER I,DE SMEDT S C,et al.Three decades of messenger RNA vaccine development[J].Nano Today,2019,28:100766.DOI:10.1016/j.nantod.2019.100766.
[19]VIERBUCHEN T,STEIN K,HEINE H.RNA is taking its Toll:Impact of RNA-specific Toll-like receptors on health and disease[J].Allergy,2019,74(2):223-235.DOI:10.1111/all.13680.
[20]KAWAI T,AKIRA S.Tolllike receptor and RIG-1-like receptor signaling[J].Ann N Y Acad Sci,2008,1143(1):1-20.DOI:10.1196/annals.1443.020.
[21]KARIKóK,MURAMATSU H,WELSH F A,et al.Incorporation of pseudouridine into m RNA yields superior nonimmunogenic vector with increased translational capacity and biological stability[J].Mol Ther,2008,16(11):1833-1840.DOI:10.1038/mt.2008.200.
[22]WANG Y,ZHANG L,XU Z,et al.m RNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma[J].Mol Ther,2018,26(2):420-434.DOI:10.1016/j.ymthe.2017.11.009.
[23]NANCE K D,MEIER J L.Modifications in an emergency:the role of N1-methylpseudouridine in COVID-19 vaccines[J].ACS Cent Sci,2021,7(5):748-756.DOI:10.1021/acscentsci.1c00197.
[24]KARIKóK,MURAMATSU H,LUDWIG J,et al.Generating the optimal m RNA for therapy:HPLC purification eliminates immune activation and improves translation of nucleoside-modified,protein-encoding m RNA[J].Nucleic Acids Res,2011,39(21):e142.DOI:10.1093/nar/gkr695.
[25]CHEN C Y A,SHYU A B.Rapid deadenylation triggered by a nonsense codon precedes decay of the RNAbody in a mammalian cytoplasmic nonsense-mediated decay pathway[J].Mol Cell Biol,2003,23(14):4805-4813.DOI:10.1128/MCB.23.14.4805-4813.2003.
[26]HOLTKAMP S,KREITER S,SELMI A,et al.Modification of antigen-encoding RNA increases stability,translational efficacy,and T-cell stimulatory capacity of dendritic cells[J].Blood,2006,108(13):4009-4017.DOI:10.1182/blood-2006-04-015024.
[27]BEDNAREK S,MADAN V,SIKORSKI P J,et al.m RNAs biotinylated within the 5′cap and protected against decapping:new tools to capture RNA-protein complexes[J].Philos Trans R Soc Lond B Biol Sci,2018,373(1762):20180167.DOI:10.1098/rstb.2018.0167.
[28]AUGUST A,ATTARWALA H Z,HIMANSU S,et al.A phase 1 trial of lipid-encapsulated m RNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus[J].Nat Med,2021,27(12):2224-2233.DOI:10.1038/s41591-021-01573-6.
[29]MCKINLAY C J,BENNER N L,HAABETH O A,et al.Enhanced m RNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters[J].Proc Natl Acad Sci U S A,2018,115(26):E5859-E5866.DOI:10.1073/pnas.1805358115.
[30]CAPASSO PALMIERO U,KACZMAREK J C,FENTON O S,et al.Poly (β-amino ester)-co-poly(caprolactone) Terpolymers as Nonviral Vectors for m RNA Delivery In Vitro and In Vivo[J].Adv Healthc Mater,2018,7(14):1800249.DOI:10.1002/adhm.201800249.
[31]WANG Y,TANG J,YANG Y,et al.Functional Nanoparticles with a Reducible Tetrasulfide Motif to Upregulate m RNA Translation and Enhance Transfection in Hard-to-Transfect Cells[J].Angew Chem Int Ed Engl,2020,132(7):2717-2721.DOI:10.1002/anie.201914264.
[32]KONG N,ZHANG R,WU G,et al.Intravesical delivery of KDM6A-m RNA via mucoadhesive nanoparticles inhibits the metastasis of bladder cancer[J].Proc Natl Acad Sci U S A,2022,119(7):e2112696119.DOI:10.1073/pnas.2112696119.
[33]HOU X,ZAKS T,LANGER R,et al.Lipid nanoparticles for m RNA delivery[J].Nat Rev Mater,2021,6(12):1078-1094.DOI:10.1038/s41578-021-00358-0.
[34]JEONG M,LEE Y,PARK J,et al.Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications[J].Adv Drug Deliv Rev,2023,200:114990.DOI:10.1016/j.addr.2023.114990
[35]AKINC A,MAIER M A,MANOHARAN M,et al.The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs[J].Nat Nanotechnol,2019,14(12):1084-1087.DOI:10.1038/s41565-019-0591-y.
[36]ALBERTSEN C H,KULKARNI J A,WITZIGMANN D,et al.The role of lipid components in lipid nanoparticles for vaccines and gene therapy[J].Adv Drug Deliv Rev,2022,188:114416.DOI:10.1016/j.addr.2022.114416.
[37]CHATTERJEE S,KON E,SHARMA P,et al.Endosomal escape:A bottleneck for LNP-mediated therapeutics[J].Proc Natl Acad Sci U S A,2024,121(11):e2307800120.DOI:10.1073/pnas.2307800120.
[38]KON E,ELIA U,PEER D.Principles for designing an optimal m RNA lipid nanoparticle vaccine[J].Curr Opin Biotechnol,2022,73:329-336.DOI:10.1016/j.copbio.2021.09.016.
[39]YANG W,MIXICH L,BOONSTRA E,et al.Polymerbased m RNA delivery strategies for advanced therapies[J].Adv Healthc Mater,2023,12(15):2202688.DOI:10.1002/adhm.202202688.
[40]TARACH P,JANASZEWSKA A.Recent advances in preclinical research using PAMAM dendrimers for cancer gene therapy[J].Int J Mol Sci,2021,22(6):2912.DOI:10.3390/ijms22062912.
[41]O’BRIEN K,BREYNE K,UGHETTO S,et al.RNA delivery by extracellular vesicles in mammalian cells and its applications[J].Nat Rev Mol Cell Biol,2020,21(10):585-606.DOI:10.1038/s41580-020-0251-y.
[42]VALADI H,EKSTR?M K,BOSSIOS A,et al.Exosome-mediated transfer of m RNAs and micro RNAs is a novel mechanism of genetic exchange between cells[J].Nat Cell Biol,2007,9(6):654-659.DOI:10.1038/ncb1596.
[43]SKOG J,WüRDINGER T,VAN RIJN S,et al.Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers[J].Nat Cell Biol,2008,10(12):1470-1476.DOI:10.1038/ncb1800.
[44]MAUGERI M,NAWAZ M,PAPADIMITRIOU A,et al.Linkage between endosomal escape of LNP-m RNAand loading into EVs for transport to other cells[J].Nat Commun,2019,10(1):4333.2019;10(1):4333.DOI:10.1038/s41467-019-12275-6.
[45]SAMSA M M,DUPUY L C,BEARD C W,et al.Self-amplifying RNA vaccines for Venezuelan equine encephalitis virus induce robust protective immunogenicity in mice[J].Mol Ther,2019,27(4):850-865.DOI:10.1016/j.ymthe.2018.12.013.
[46]O’HAGAN D T,OTT G S,DE GREGORIO E,et al.The mechanism of action of MF59-an innately attractive adjuvant formulation[J].Vaccine,2012,30(29):4341-4348.DOI:10.1016/j.vaccine.2011.09.061.
[47]GóMEZ-AGUADO I,RODRíGUEZ-CASTEJóN J,VICENTE-PASCUAL M,et al.Nanomedicines to deliver m RNA:state of the art and future perspectives[J].Nanomaterials,2020,10(2):364.DOI:10.3390/nano10020364.
[48]HUANG Q,JI K,TIAN S,et al.A single-dose m RNAvaccine provides a long-term protection for h ACE2transgenic mice from SARS-Co V-2[J].Nat Commun,2021,12(1):776.DOI:10.1038/s41467-021-21037-2.
[49]SZABóG T,MAHINY A J,VLATKOVIC I.COVID-19 m RNA vaccines:Platforms and current developments[J].Mol Ther,2022,30(5):1850-1868.DOI:10.1016/j.ymthe.2022.02.016.
[50]LAURINI G S,MONTANARO N,BROCCOLI M,et al.Real-life safety profile of m RNA vaccines for COVID-19:an analysis of VAERS database[J].Vaccine,2023,41(18):2879-2886.DOI:10.1016/j.vaccine.2023.03.054.
[51]IAVARONE C,O’HAGAN D T,YU D,et al.Mechanism of action of m RNA-based vaccines[J].Expert Rev Vaccines,2017,16(9):871-881.DOI:10.1080/14760584.2017.1355245.
[52]KEEHNER J,HORTON L E,PFEFFER M A,et al.SARS-Co V-2 infection after vaccination in health care workers in California[J].N Engl J Med,2021,384(18):1774-1775.DOI:10.1056/NEJMc2101927.
[53]XU K,LEI W,KANG B,et al.A novel m RNA vaccine,SYS6006,against SARS-Co V-2[J].Front Immunol,2023,13:1051576.DOI:10.3389/fimmu.2022.1051576.
[54]LIANG F,LINDGREN G,LIN A,et al.Efficient targeting and activation of antigen-presenting cells in vivo after modified m RNA vaccine administration in rhesus macaques[J].Mol Ther,2017,25(12):2635-2647.DOI:10.1016/j.ymthe.2017.08.006.
[55]FREYN A W,DA SILVA J R,ROSADO V C,et al.A multi-targeting,nucleoside-modified m RNA influenza virus vaccine provides broad protection in mice[J].Mol Ther,2020,28(7):1569-1584.DOI:10.1016/j.ymthe.2020.04.018.
[56]BAHL K,SENN J J,YUZHAKOV O,et al.Preclinical and clinical demonstration of immunogenicity by m RNA vaccines against H10N8 and H7N9 influenza viruses[J].Mol Ther,2017,25(6):1316-1327.DOI:10.1016/j.ymthe.2017.03.035.
[57]FELDMAN R A,FUHR R,SMOLENOV I,et al.m RNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials[J].Vaccine,2019,37(25):3326-3334.10.1016/j.vaccine.2019.04.074.
[58]DYBUL M,ATTOYE T,BAPTISTE S,et al.The case for an HIV cure and how to get there[J].Lancet HIV,2021,8(1):e51-e58.DOI:10.1016/S2352-3018(20)30232-0.
[59]SAIED A R A.m RNA vaccines and clinical research in Africa-From hope to reality[J].Int J Surg,2022,105:106833.DOI:10.1016/j.ijsu.2022.106833.
[60]BRISSE M,VRBA S M,KIRK N,et al.Emerging concepts and technologies in vaccine development[J].Front Immunol,2020,11:583077.DOI:10.3389/fimmu.2020.583077.
[61]LIU C,SHI Q,HUANG X,et al.m RNA-based cancer therapeutics[J].Nat Rev Cancer,2023,23(8):526-543.DOI:10.1038/s41568-023-00586-2.
[62]BIONTECH S E.Bio NTech receives FDA fast track designation for its Fix Vac candidate BNT111 in advanced melanoma.Globe Newswire[EB/OL].(2021-11-19)[2024-12-19].https：//investors.biontech.de/news-releases/news-release-details/biontech-receivesfda-fast-track-designation-its-fixvac.
[63]BLASS E,OTT P A.Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J].Nat Rev Clin Oncol,2021,18(4):215-229.DOI:10.1038/s41571-020-00460-2.
[64]PATEL M R,BAUER T M,JIMENO A,et al.Aphase I study of m RNA-2752,a lipid nanoparticle encapsulating m RNAs encoding human OX40L,IL-23,and IL-36γ,for intratumoral (i Tu) injection alone and in combination with durvalumab[J].J Clin Oncol,2020,38(15):3092.DOI:10.1200/JCO.2020.38.15_suppl.3092.
[65]REN J,LIU X,FANG C,et al.Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition[J].Clin Cancer Res,2017,23(9):2255-2266.DOI:10.1158/1078-0432.CCR-16-1300.
[66]XIAO Y,CHEN J,ZHOU H,et al.Combining p53m RNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy[J].Nat Commun,2022,13(1):758.DOI:10.1038/s41467-022-28279-8.
[67]ROHNER E,YANG R,FOO K S,et al.Unlocking the promise of m RNA therapeutics[J].Nat Biotechnol,2022,40(11):1586-1600.DOI:10.1038/s41587-022-01491-z.
[68]ANTTILA V,SARASTE A,KNUUTI J,et al.Direct intramyocardial injection of VEGF m RNA in patients undergoing coronary artery bypass grafting[J].Mol Ther,2023,31(3):866-874.DOI:10.1016/j.ymthe.2022.11.017.
[69]ZHA W,WANG J,GUO Z,et al.Efficient delivery of VEGF-A m RNA for promoting diabetic wound healing via ionizable lipid nanoparticles[J].Int J Pharm,2023,632:122565.DOI:10.1016/j.ijpharm.2022.122565.
[70]RUSSICK J,DELIGNAT S,MILANOV P,et al.Correction of bleeding in experimental severe hemophilia A by systemic delivery of factorⅧ-encoding m RNA[J].Haematologica,2019,105(4):1129.DOI:10.3324/haematol.2018.210583.
[71]LEE J H,HAN J P.In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia[J].Mol Diagn Ther,2024,28(3):239-248.DOI:10.1007/s40291-024-00705-1.
[72]NAGAHARA A H,WILSON B R,IVASYK I,et al.MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates[J].Gene Ther,2018,25(2):104-114.DOI:10.1038/s41434-018-0010-2.
[73]FUKUSHIMA Y,UCHIDA S,IMAI H,et al.Treatment of ischemic neuronal death by introducing brain-derived neurotrophic factor m RNA using polyplex nanomicelle[J].Biomaterials,2021,270:120681.DOI:10.1016/j.biomaterials.2021.120681.
[74]KAZEMIAN P,YU S Y,THOMSON S B,et al.Lipid-nanoparticle-based delivery of CRISPR/Cas9genome-editing components[J].Mol Pharm,2022,19(6):1669-1686.DOI:10.1021/acs.molpharmaceut.1c00916.
[75]XU X,LIU C,WANG Y,et al.Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment[J].Adv Drug Deliv Rev,2021,176:113891.DOI:10.1016/j.addr.2021.113891.
[76]BERLING E,NICOLLE R,LAFORêT P,et al.Gene therapy review:Duchenne muscular dystrophy case study[J].Rev Neurol (Paris),2023,179(1-2):90-105.DOI:10.1016/j.neurol.2022.11.005.
[77]PITRONE P,CATTAFI A,MAGNANI F,et al.Spontaneous transverse colon volvulus in a patient with Duchenne muscular dystrophy:An unreported complication[J].Radiol Case Rep,2023,18(3):1306-1310.DOI:10.1016/j.radcr.2022.12.062.
[78]KENJO E,HOZUMI H,MAKITA Y,et al.Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 m RNA into skeletal muscle in mice[J].Nat Commun,2021,12(1):7101.DOI:10.1038/s41467-021-26714-w.
[79]MAO X,WANG G,WANG Z,et al.Theranostic Lipid Nanoparticles for Renal Cell Carcinoma[J].Adv Mater,2023:2306246.DOI:10.1002/adma.202306246.
[80]DILLIARD S A,SIEGWART D J.Passive,active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs[J].Nat Rev Mater,2023,8(4):282-300.DOI:10.1038/s41578-022-00529-7.
[81]HERRERA-BARRERA M,RYALS R C,GAUTAM M,et al.Peptide-guided lipid nanoparticles deliver m RNAto the neural retina of rodents and nonhuman primates[J].Sci Adv,2023,9(2):eadd4623.DOI:10.1126/sciadv.add4623.
[82]XU M,QI Y,LIU G,et al.Size-dependent in vivo transport of nanoparticles:implications for delivery,targeting,and clearance[J].ACS nano,2023,17(21):20825-20849.DOI:10.1021/acsnano.3c05853.
基本信息:
中图分类号:R450
引用信息:
[1]罗秋思,肖玉玲,洪学传.mRNA疗法：开启现代医学治疗的新纪元[J].新兴科学和技术趋势,2025,4(02):117-128.
基金信息:
国家自然科学基金(22477129)
2024-12-27
2024
2025-04-27
2025
2
2025-03-26
2025-03-26
2025-03-26